Andrew James King - 10 Feb 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role: Chief Scientific Officer
Signature: /s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 10 Feb 2022
Net transactions value: -$32,400
Form type: 4
Filing time: 11 Feb 2022, 16:26:33 UTC
Previous filing: 02 Feb 2022
Next filing: 23 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KDNY	Common Stock	Options Exercise	$875	+2,500	+61%	$0.3500^*	6,594	10 Feb 2022	Direct
transaction	KDNY	Common Stock	Sale	$33,275	-2,500	-38%	$13.31	4,094	10 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KDNY	Stock Option (right to buy)	Options Exercise	$0	-2,500	-3.5%	$0.000000	68,047	10 Feb 2022	Common Stock	2,500	$0.3500	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.